Olmesartan Medoxomil, Amlodipine & Hydrochlorothiazide Tablet

OLMEROOT-ACH

Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets

Division: DIABGLYM

Composition

Each tablet contains:

Olmesartan Medoxomil IP — 20 mg

Amlodipine IP — 5 mg

Hydrochlorothiazide IP — 12.5 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Oral tablet

Product Description

OLMEROOT-ACH is an advanced triple-combination antihypertensive formulation containing Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide, designed for the effective management of moderate to severe hypertension and long-term cardiovascular risk reduction. This combination targets three complementary mechanisms involved in blood pressure regulation, providing superior blood pressure control and enhanced cardiovascular and renal protection.

Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation and protects cardiovascular and renal function. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle and reduces peripheral vascular resistance. Hydrochlorothiazide is a thiazide diuretic that enhances sodium and water excretion while contributing to effective blood pressure reduction.

OLMEROOT-ACH is particularly beneficial for patients with uncontrolled hypertension, resistant hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, left ventricular hypertrophy, and patients requiring intensive combination antihypertensive therapy.

Technical Knowledge of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide

Olmesartan Medoxomil is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, and vascular remodeling.

Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation and reduction of peripheral vascular resistance.

Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion, reducing plasma volume, and contributing to long-term blood pressure reduction.

The combination of Olmesartan, Amlodipine, and Hydrochlorothiazide provides complementary antihypertensive mechanisms with superior efficacy compared with dual therapy and improved cardiovascular and renal protection.

Mechanism of Action

Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal tissues.

Amlodipine relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, and provides sustained antihypertensive action.

Hydrochlorothiazide promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances overall antihypertensive efficacy.

Key Benefits

Powerful triple antihypertensive mechanism

Superior reduction of systolic and diastolic blood pressure

Provides sustained 24-hour blood pressure control

Supports cardiovascular and renal protection

Reduces peripheral vascular resistance

Improves vascular compliance

Effective diuretic support

Effective in resistant and uncontrolled hypertension

Suitable for long-term hypertension management under medical supervision

Clinical Applications

OLMEROOT-ACH is commonly prescribed for moderate to severe hypertension, resistant hypertension, uncontrolled hypertension requiring triple therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, left ventricular hypertrophy, and long-term cardiovascular risk reduction.

Facts About Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide

Triple-combination antihypertensive therapy is widely recommended for patients with uncontrolled hypertension requiring intensive blood pressure management. Olmesartan provides RAAS blockade and organ protection, Amlodipine provides sustained vasodilation, and Hydrochlorothiazide provides effective diuretic support. This combination offers comprehensive blood pressure control with strong evidence for reduction of cardiovascular events and target organ damage.

Key Facts

Advanced triple antihypertensive combination therapy

Olmesartan Medoxomil for vascular and renal protection

Amlodipine for sustained arterial vasodilation

Hydrochlorothiazide for effective diuretic support

Provides 24-hour comprehensive blood pressure control

Effective in resistant hypertension and high-risk cardiovascular patients

Evidence-based cardiovascular combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

OLMEROOT-ACH is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of resistant hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this advanced combination.

Why Choose OLMEROOT-ACH for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

OLMEROOT-ACH from DIABGLYM combines powerful triple blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan, Amlodipine, and Hydrochlorothiazide formulation.